Company Product Description Indication Status
Phase II
Cortexyme Inc., of South San Francisco Atuzaginstat Gingipain inhibitor Alzheimer's disease Enrollment reached 500
Imara Inc., of Boston IMR-687 Small-molecule inhibitor of PDE9 Sickle cell disease First patient dosed
Phase III
Lupin Pharmaceuticals Inc., of Baltimore Solosec (secnidazole) 5-nitroimidazole antimicrobial Trichomoniasis Single-dose treatment resulted in a highly statistically significant response rate, or microbiological cure, in 92%-95% of patients vs. 1.5%-1.7% in placebo group

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments